Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 1:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 17,751 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Population Clear all

Conditions: Brain Concussion
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 12 Years to 40 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Change in Bone Mineral Density, Bone Loss
Interventions: drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet; Drug
Lead sponsor: Insud Pharma; Industry
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 1,536 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 27
States / cities: Phoenix, Arizona • Aurora, Colorado • Boynton Beach, Florida + 17 more

Conditions: Ischemic Stroke; Ischemic Attack, Transient
Interventions: Milvexian, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 40 Years and older
Enrollment: 12,523 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 127
States / cities: Mesa, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 102 more

Conditions: Cystic Fibrosis
Interventions: Ivacaftor, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 39
States / cities: Birmingham, Alabama • Oakland, California • Palo Alto, California + 34 more

Conditions: Anaemia
Interventions: GSK1278863, GSK1278863 matching Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Northridge, California • San Dimas, California • Pembroke Pines, Florida + 4 more

Conditions: Diabetic Macular Edema
Interventions: bevasiranib; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Beechwood, Ohio

Conditions: Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS), Genetic Diseases, Inborn
Interventions: rilonacept 160 mg, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 7 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 24
States / cities: Little Rock, Arkansas • Palm Desert, California • Upland, California + 21 more

Conditions: Diet, Mediterranean, Health Behavior, Program Sustainability, Program Effectiveness
Interventions: Mediterranean diet Intervention; Behavioral
Lead sponsor: Harvard School of Public Health (HSPH); Other
Eligibility: 18 Years and older
Enrollment: 486 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anxiety, Depression, Depression, Postpartum, Pregnancy Related, CBT
Interventions: Coordinated Anxiety Learning and Management; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Oakland, California

Conditions: Upper Extremity Paresis
Interventions: transcranial direct current stimulation; Device
Lead sponsor: University of the Sciences in Philadelphia; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Schizophrenia, Psychotic Disorders
Interventions: M3 Program, Control; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 15 Years to 25 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Port Wine Stains
Interventions: Rapamycin cream, Pulsed dyed laser; Drug · Procedure
Lead sponsor: AFT Pharmaceuticals, Ltd.; Industry
Eligibility: Up to 10 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Corpus Christi, Texas

Conditions: Childhood Cancer Survivors
Interventions: Physical activity intervention coupled with standard post-cancer directed treatment care, Standard post-cancer directed treatment care control; Behavioral · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 10 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Autism Spectrum Disorder
Interventions: Cognitive Support Technology (CST); Behavioral
Lead sponsor: Kent State University; Other
Eligibility: Not listed
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Kent, Ohio

Conditions: Multidisciplinary Communication
Interventions: Nurse-led progressive mobility protocol, Standard of Care; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pain
Interventions: Liposomal Bupivicaine; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Shoulder Pain, Shoulder Injuries
Interventions: CRISP: Criteria-Based Approach for the Rehabilitation for Non-Operative Shoulder Injuries, Standard of Care; Other
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Color Blindness, Color Vision Defects, Color Blindness, Green, Color Blindness, Red
Interventions: Experimental Group 1: Color Correcting Lenses, Placebo Group 1: Placebo Lenses, Placebo Group 1 Crosses over to become Experimental Group 2: Color Correcting Lenses, Experimental Group 1 Crosses over to become Placebo Group 2: Placebo Lenses, Color Correcting Lenses in Subjects with Normal Color Vision; Device
Lead sponsor: University of the Incarnate Word; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetic Neuropathy
Interventions: Exercise; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Hines, Illinois

Conditions: Musculoskeletal Abnormalities, Obesity, Sarcopenic Obesity, Osteoporosis, Drug Effect
Interventions: Tirzepatide, Lifestyle toolkit; Drug · Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Baton Rouge, Louisiana • Scarborough, Maine

Conditions: Hypertension, African Americans, Diet, Carbohydrate-Restricted, Risk Reduction Behavior
Interventions: Very low carbohydrate diet, Standard DPP-GLB diet, Standard DPP-GLB program modules; Other · Behavioral
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 74 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: COVID-19
Interventions: Sodium Pyruvate, Saline; Drug · Other
Lead sponsor: Cellular Sciences, inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Virginia Gardens, Florida • Springfield, Missouri

Conditions: Celiac Disease
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 2 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Abscess
Interventions: Standard of Care (SoC), Irrisept Delivery System; Device
Lead sponsor: Irrimax Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

Examination of Balance, Vestibular, and Ocular Functions and Activity Following Concussion

LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema

Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

Feeding America's Bravest: Mediterranean Diet-Based Interventions to Change Firefighters' Eating Habits

CALM for Pregnant and Post-Partum Women

Priming With tDCS: Expanding the Window of Recovery in Chronic Stroke

A Multi-modal Approach to Addressing Cardiovascular Risk and Building Resilience in Youths With Psychosis

Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains

Exercise and Pain in CCS

Cognitive Support Technology for Postsecondary Students With Autism Spectrum Disorder

Multidisciplinary Teamwork Perceptions When Mobilizing Ventilated Neurosurgery Patients

Liposomal Bupivacaine in Ambulatory Hand Surgery

Efficacy of a Criteria Based Clinical Pathway for Rehabilitation of Shoulder Injuries

Impact of Color Correcting Lenses on Color Vision Deficiency

Exercise-facilitated Neurorehabilitation in Diabetic Neuropathy

GLP-1R Actions on Muscle and the Skeleton

Giving a Low Carbohydrate Diet to Overcome Hypertension

Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection

Gut Permeability Assessment in Celiac and Gluten Sensitive Children

The Effect of Wound Irrigation With Irrisept on Abscess Healing (Irrisept UF Study)